SCHEMBL26401754

SCHEMBL26401754

CCC1CC2(C1)CN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.45
EPHX2 P34913 1/20 0.40
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GPR119 Q8TDV5 4/20 0.40
HPGD P15428 1/20 0.38
NAMPT P43490 1/20 0.37
EHMT2 Q96KQ7 1/20 0.37
OXTR P30559 1/20 0.37
AVPR1A P37288 1/20 0.37
GPR183 P32249 1/20 0.37
KRAS P01116 1/20 0.36
RECQL P46063 1/20 0.36
EPHX1 P07099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9994141 0.88 GPR119 (0.42) NR1H2EPHX2USP2SMN1; SMN2GPR119
SCHEMBL30898345 0.88 GPR119 (0.44) NR1H2EPHX2USP2SMN1; SMN2GPR119
SCHEMBL18393607 0.87 NR1H2 (0.56) NR1H2EPHX2USP2SMN1; SMN2GPR119
SCHEMBL31644676 0.87 GPR119 (0.41) NR1H2EPHX2USP2SMN1; SMN2GPR119
SCHEMBL25413411 0.86 NR1H2 (0.44) NR1H2EPHX2USP2SMN1; SMN2GPR119
SCHEMBL29110595 0.86 NR1H2 (0.44) NR1H2EPHX2USP2SMN1; SMN2GPR119
SCHEMBL21997549 0.86 NR1H2 (0.44) NR1H2EPHX2USP2SMN1; SMN2GPR119
SCHEMBL18298972 0.84 NR1H2 (0.43) NR1H2EPHX2USP2SMN1; SMN2GPR119
SCHEMBL31104126 0.84 NR1H2 (0.47) NR1H2EPHX2USP2SMN1; SMN2GPR119
SCHEMBL25726262 0.84 GPR119 (0.54) NR1H2EPHX2USP2SMN1; SMN2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 ENPP1, ENPP3, SMPD1 NR1H2 4007/4885EPHX2 1237/4885USP2 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.